Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
John W. Kozarich, a director of Ligand Pharmaceuticals Inc (LGND), sold 467 shares on April 1, 2026, for roughly $94,440 under a pre-arranged trading plan. The transaction comes amid strong quarterly results for Ligand and mixed valuation signals from market analytics and analysts alike. Following the trades Kozarich holds 42,253 shares.
V-Co Investors 3 LLC, a ten percent owner of Vivos Therapeutics, Inc. (VVOS), bought 1,353,625 shares of common stock for $1.34 per share on March 31, 2026, totaling $1,813,857. The investor also acquired multiple classes of warrants and pre-funded warrants, while the company completed an agreement to immediately exercise outstanding warrants at a …
Maria VG Woods, Executive Vice President - General Counsel at National CineMedia, sold 12,066 shares of common stock on April 1, 2026, at $3.04 per share for proceeds of $36,680. The transaction occurred as the stock trades near its 52-week low and after a recent vesting of restricted stock units. Separately, National CineMedia reported a 7.9% rise…
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 38,120 shares on April 1 and 2, 2026 for about $553,693 at weighted average prices between $14.45 and $14.60. On those same dates she exercised options to buy 29,444 shares at $7.27 for $214,057. The stock trades at $14.81, up 86.5% year over year. InvestingPro…
Zenas BioPharma director Lu Hongbo purchased 3,768 shares of the company's common stock on March 31, 2026, for $18.63 per share, a total of $70,197. The purchase occurred amid mixed market performance for the shares and a series of financing moves and clinical milestones, including positive Phase 2 data for obexelimab and recent public offerings an…
Accel Entertainment CEO Andrew H. Rubenstein sold 45,000 shares of Class A-1 common stock on April 1, 2026, for roughly $497,276. The company reported solid fourth-quarter 2025 results, marking its 13th consecutive quarter of beating estimates, and received an upward price-target revision from Citizens.
Ingredion Inc. director Jorge A. Uribe reported a small open-market sale of company shares and receipt of stock as annual director retainer. The filings show a fractional sale worth $83, issuance of 380 shares as compensation, tax-withholding of part of the retainer, and the insider's updated direct and indirect holdings. The disclosures arrive as …
Axcelis Technologies President and CEO Russell Low sold 1,244 shares on April 1, 2026, for $94.06 each, totaling $117,010. Low retains 132,282 shares, including 83,480 restricted stock units subject to forfeiture under the 2012 Equity Incentive Plan. The sale was carried out under a Rule 10b5-1 trading plan adopted December 11, 2025. Axcelis report…
CarGurus Chief People Officer Jennifer Ladd Hanson disclosed two recent stock dispositions totaling $128,980 tied to a prearranged trading plan and tax liabilities on vested restricted stock units. The transactions come while the shares trade below the year-to-date level and as analysts adjust forecasts and price targets following quarterly results…
EverQuote, Inc. NASDAQ:EVER Chief Financial Officer Joseph Sanborn sold 650 shares of Class A Common Stock on April 2, 2026, under a Rule 10b5-1 plan to satisfy tax liabilities from a restricted stock unit vesting. The sale coincides with shares trading near a 52-week low while InvestingPro's Fair Value assessment indicates the stock may be underva…
Christine Ring, Chief Legal Officer of Nurix Therapeutics (NRIX), sold 8,148 shares on April 2, 2026, for a total of $124,148 at a weighted average price of $15.2367. The sale - executed under a Rule 10b5-1 trading plan - leaves Ring with 26,453 shares. Nurix also amended an equity distribution agreement with Piper Sandler to permit up to $413.65 m…
Daphne Karydas, a member of Mineralys Therapeutics' board, sold 3,000 shares on March 31, 2026 for $75,000 and exercised options to acquire 3,000 shares at $12.02 the same day. The stock has gained strongly over the past year, while analysts differ on fair value amid progress toward a potential commercial launch of lorundrostat and a recent quarter…
Andrew Reardon, Chief Legal Officer and Secretary at Ligand Pharmaceuticals (LGND), sold nearly 5,000 shares on April 1, 2026 under a pre-arranged trading plan and exercised options to acquire 5,000 shares the same day. The transactions leave Reardon with a direct holding of 41,382 shares. The moves come as Ligand posted robust fourth-quarter and f…
Mineralys Therapeutics Chief Executive Jon Congleton sold 74,900 shares on March 31, 2026, for $1.97 million under a Rule 10b5-1 plan. The company reported a better-than-expected Q4 2025 EPS of -0.4, named a new Chief Legal Officer, and faces divergent analyst price targets and investor focus on rising general and administrative expenses as it posi…
Pagaya Technologies Ltd. Chief Financial Officer Evangelos Perros sold 13,004 Class A Ordinary Shares on April 1, 2026, at $11.34 per share for about $147,465. The transaction followed the conversion of 22,766 restricted stock units. Pagaya meanwhile closed two large auto-related securitizations and faces updated analyst views after mixed quarterly…
Pale Fire Capital SE and related entities purchased a total of $10.4 million of Phreesia, Inc. (PHR) common shares across transactions executed March 31 through April 2, 2026. The acquisitions raise Pale Fire Capital SICAV a.s.'s direct stake to 8,924,329 shares. The activity takes place while Phreesia shares trade close to their 52-week low and fo…
Houlihan Lokey General Counsel Christopher M. Crain sold 500 shares of Class A common stock on April 1, 2026, for $71,700 and simultaneously converted 500 Class B shares into Class A shares at no cost. The transaction leaves Crain with no direct Class A holdings while he retains indirect exposure through the HL Voting Trust. The move comes as HLI s…
Andrea Renee Bortner, Executive Vice President and Chief Human Resources Officer of Grocery Outlet Holding Corp (NASDAQ: GO), sold 1,851 shares on April 1, 2026 under a pre-arranged Rule 10b5-1 trading plan. The transaction, valued at $12,957, follows a six-month 55% drop in the company’s stock and recent fourth-quarter results that missed certain …
Helen Torley, President and CEO of Halozyme Therapeutics (NASDAQ: HALO), sold 39,000 shares of company stock across multiple transactions on April 1 and April 2, 2026, generating roughly $2.59 million. On the same dates she exercised options to acquire 40,000 shares at $12.07 each, costing $482,800. The transactions are disclosed in an SEC Form 4 f…
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn sold 4,683 shares on April 1, 2026, for $20.97 apiece, totaling $98,202. The transaction, executed under a Rule 10b5-1 trading plan, left Horn with 80,351 shares. Meanwhile, the FDA accepted a resubmitted Biologics License Application for UX111 with a Prescription Drug User Fee Act …
Cardlytics Inc. Chief Executive Officer Amit Gupta sold 116,774 shares of common stock on April 1 and April 2, 2026, for approximately $118,425 in aggregate. The transactions occurred while the stock traded at $1.13, down 52% over six months. The company posted a slight revenue beat for fiscal 2025 fourth quarter and completed the sale of its Bridg…
Cardlytics Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer reported a sale of 40,296 shares of company stock on April 1, 2026, at a weighted average price of $0.99 for proceeds of $39,893, while on the same day exercising restricted stock units that resulted in the acquisition of 85,590 shares. The company recently posted mixed fourth-quart…
Rush Street Interactive Chief Executive Officer Richard Todd Schwartz sold 90,482 shares of the company’s Class A common stock on April 1, 2026, for roughly $1.99 million under a pre-arranged 10b5-1 plan. The divestiture occurred as RSI shares traded near a 52-week peak following a 99% gain over the past 12 months. Multiple analysts have recently a…
Director Stuart N. Bernstein sold 4,071 shares of Xos, Inc. common stock on March 31, 2026, in a trade totaling $6,693. The company reported a shift to profitability and positive cash flow for 2025 despite a drop in annual revenue; the shares have also been under recent pressure and are trading near a 52-week low.
Rush Street Interactive Chief Operating Officer Mattias Stetz sold 20,000 Class A shares on April 1, 2026, generating proceeds of $441,444 at a weighted average price of $22.0722. The trade, carried out under a pre-arranged 10b5-1 plan, occurred as RSI traded close to a 52-week high of $22.80 following a nearly 99% gain over the past year. Stetz co…
